SCHEMBL6440883

SCHEMBL6440883

N#Cc1c(SCc2ccccc2)nc(N)nc1-c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 16/20 0.67
ADORA2A P29274 15/20 0.67
ADORA3 P0DMS8 1/20 0.67
ALDH1A1 P00352 2/20 0.57
MEN1 O00255 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C9 P11712 1/20 0.57
HPGD P15428 1/20 0.57
CYP2C19 P33261 1/20 0.57
PPARG P37231 1/20 0.57
HTT P42858 1/20 0.57
KMT2A Q03164 1/20 0.57
NCOA2 Q15596 1/20 0.57
NCOA1 Q15788 1/20 0.57
ACMSD Q8TDX5 1/20 0.55
RET P07949 1/20 0.54
MAPK1 P28482 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ADORA2B P29275 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441334 0.88 ADORA1 (0.61) ADORA1ADORA2AADORA3ALDH1A1MEN1
SCHEMBL6444715 0.85 ALDH1A1 (0.65) ADORA1ADORA2AADORA3ALDH1A1MEN1
SCHEMBL5041646 0.85 ADORA1 (0.57) ADORA1ADORA2AADORA3ALDH1A1MEN1
SCHEMBL6442257 0.83 ADORA2A (0.69) ADORA1ADORA2AALDH1A1HPGDADORA2B
SCHEMBL5041333 0.83 MEN1 (0.69) ADORA1ADORA2AADORA3ALDH1A1MEN1
SCHEMBL6442467 0.82 ADORA1 (0.69) ADORA1ADORA2AADORA3ALDH1A1HPGD
SCHEMBL6446335 0.82 ADORA1 (0.60) ADORA1ADORA2AADORA3ALDH1A1MEN1
SCHEMBL6440806 0.81 ADORA1 (0.58) ADORA1ADORA2AADORA3ALDH1A1MEN1
SCHEMBL6442594 0.80 ADORA1 (0.71) ADORA1ADORA2AADORA3CYP1A2CYP2C9
SCHEMBL6442931 0.80 ADORA1 (0.57) ADORA1ADORA2AADORA3ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA1 3/4885ADORA2A 1/4885ADORA3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.